LPL Financial’s AbCellera Biologics ABCL Stock Holding History

LPL Financial’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.55M	Buy	106,295 +16,794	+19%	+$159K	﹤0.01%	4062
2026 Q2	$703K	Sell	89,501 -32,312	-27%	-$158K	﹤0.01%	4742
2026 Q1	$425K	Buy	121,813 +73,109	+150%	+$263K	﹤0.01%	4909
2025 Q4	$167K	Buy	48,704 +12,954	+36%	+$57.8K	﹤0.01%	5498
2025 Q3	$180K	Buy	35,750 +17,526	+96%	+$77.2K	﹤0.01%	5385
2025 Q2	$62.5K	Buy	+18,224	New	+$45.4K	﹤0.01%	5338
2024 Q4	–	Sell	-13,313	Closed	-$34.6K	–	5275
2024 Q3	$34.6K	Sell	13,313 -5,750	-30%	-$15.9K	﹤0.01%	5037
2024 Q2	$56.4K	Sell	19,063 -46,680	-71%	-$177K	﹤0.01%	4826
2024 Q1	$298K	Buy	+65,743	New	+$335K	﹤0.01%	4205

Other funds holding ABCL

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

J.W. Cole Advisors Tampa, Florida $5.93B AUM 23.96% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LPL Financial's ABCL Position: Q3 2026 in Review

LPL Financial increased its AbCellera Biologics (ABCL) stake by 19% in Q3 2026, buying an estimated $159K and bringing the position to 106,295 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

LPL Financial first reported a position in ABCL in Q1 2024 and has held it in 9 quarters since. 49 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

LPL Financial held 106,295 shares of AbCellera Biologics worth $1.55M as of Q3 2026.
LPL Financial bought 16,794 AbCellera Biologics shares in Q3 2026, an estimated $159K.
AbCellera Biologics made up ﹤0.01% of LPL Financial's portfolio in Q3 2026, its #4062 holding.
LPL Financial first reported a position in AbCellera Biologics in Q1 2024 and has held it in 9 quarters since.
49 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on LPL Financial's 13F filing for Q3 2026, filed 6 Nov 2026.